OUR PIPELINE

We believe that our potential therapies will have the ability to transform the lives of people with a wide spectrum of diseases, including many types of cancer. Through our pipeline of proprietary enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors, we are building the next wave of precision therapies.

Program/Target Indication Disease Discovery Phase 1 Phase 2 Phase 3 Global Rights
FHD-286
(BRG1 / BRM)
AML Combination Study Relapsed/Refractory AML
Foghorn Therapeutics
FHD-909 (BRM Selective)
BRG1 Mutated Cancers BRG1 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Foghorn Therapeutics and Loxo Oncology at Lilly
Selective BRM
BRG1 Mutated Cancers BRG1 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Foghorn Therapeutics and Loxo Oncology at Lilly
Selective EP300
CBP Mutated & Subsets of EP300 Dependent Cancers EP300 dependent cancers (e.g., prostate, DLBCL),
CBP mutant cancers (e.g., ~9-10% of NSCLC, bladder, melanoma)
Foghorn Therapeutics
Selective CBP
EP300 Mutated Cancers EP300 mutant cancers (e.g., ~5-10% of bladder, gastric, breast, NSCLC, colorectal)
Foghorn Therapeutics
Selective ARID1B
ARID1A Mutated Cancers ARID1A mutant cancers (~5% of all solid tumors)
Foghorn Therapeutics
Undisclosed
Undisclosed Undisclosed
Foghorn Therapeutics
Partnered Program (Undisclosed)
Undisclosed Undisclosed
Foghorn Therapeutics and Loxo Oncology at Lilly
3 Discovery Programs (Undisclosed)
Undisclosed Undisclosed
Foghorn Therapeutics and Loxo Oncology at Lilly
Additional Discovery  

Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors

 

While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.

  • Enzyme Inhibitors
  • Protein Degraders
  • Transcription Factor Disruptors
  • Undisclosed
  • Enzyme Inhibitors
  • Protein Degraders
  • Transcription Factor Disruptors
  • Undisclosed
FHD-286
(BRG1 / BRM)
Relapsed/Refractory AML
Global Rights: Foghorn Therapeutics

AML Combination Study

Phase 1
FHD-909 (BRM Selective)
BRG1 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Global Rights: Foghorn Therapeutics

BRG1 Mutated Cancers

Discovery
Selective BRM
BRG1 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Global Rights: Foghorn Therapeutics

BRG1 Mutated Cancers

Discovery
Selective EP300
EP300 dependent cancers (e.g., prostate, DLBCL),
CBP mutant cancers (e.g., ~9-10% of NSCLC, bladder, melanoma)
Global Rights: Foghorn Therapeutics

CBP Mutated & Subsets of EP300 Dependent Cancers

Discovery
Selective CBP
EP300 mutant cancers (e.g., ~5-10% of bladder, gastric, breast, NSCLC, colorectal)
Global Rights: Foghorn Therapeutics

EP300 Mutated Cancers

Discovery
Selective ARID1B
ARID1A mutant cancers (~5% of all solid tumors)
Global Rights: Foghorn Therapeutics

ARID1A Mutated Cancers

Discovery
Undisclosed
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
Partnered Program (Undisclosed)
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
3 Discovery Programs (Undisclosed)
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
Additional Discovery

Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors

While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.

OUR LEAD CANDIDATE

FHD-286

FHD-286, is an enzymatic inhibitor of BRG1 and BRM, which are two highly similar proteins that are the ATPases, or catalytic engines, across all forms of the BAF complex. Every BAF complex includes either BRG1 or BRM. FHD-286 inhibits the function of BRG1 and BRM in cancers that are heavily dependent on BRG1 and BRM.

Target & Modality

BRG1/BRM ATPase

Highly potent, selective, allosteric, small molecule, oral enzymatic inhibitor

Initial Indications

Acute myeloid leukemia (AML)

Myelodysplastic syndromes (MDS)

Genetic Dependency

AML: Elevated BRG1-BAF / TF activity in AML blast cells

Preclinical & Discovery Programs

We have used our Gene Traffic Control® platform to discover other programs currently in the early preclinical stage, including:

  • A selective BRM inhibitor and degrader, which targets cancers with mutations in the BRG1 subunit of the BAF complex.
  • An ARID1B degrader, which targets cancers with mutations in ARID1A subunit of the BAF complex.
  • Compounds that disrupt the interactions between transcription factors and chromatin remodeling complexes.

OUR COLLABORATOR

Our collaboration with Lilly includes a co-development and co-commercialization agreement on the selective BRM oncology program and an additional undisclosed oncology target. In addition, the partnership includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control® platform.

Investor Resources

View investor portal

Find out more about our company, accomplishments, news, and latest events.